Shao-LeeLinMD

Physician

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of California (San Diego) Medical CenterFellowship, Rheumatology, 2000 - 2003
Scripps Clinic/Scripps Green HospitalFellowship, Allergy and Immunology, 1999 - 2002
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1997 - 1999
Johns Hopkins University School of MedicineClass of 1995

PubMed

261 citations
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease.
Stephan R. Targan, Brian G. Feagan, Severine Vermeire, Remo Panaccione, Gil Y. Melmed
The American Journal of Gastroenterology. 2016-08-02
37 citations
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications
Alice B. Gottlieb, Kenneth B. Gordon, Edward H. Giannini, Philip J. Mease, Juan Li
Journal of Drugs in Dermatology. 2011-03-01
126 citations
Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
Edward H. Giannini, Norman T. Ilowite, Daniel J. Lovell, Carol A. Wallace, C. E. Rabinovich
Arthritis and Rheumatism. 2009-09-01

ACELYRIN Acquires ValenzaBio, Strengthens Immunology PositionJanuary 6th, 2023
Integrated Clinical Trial Analyses Further Substantiate That Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of LifeOctober 31st, 2019
American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED)August 19th, 2019
Join now to see all